Agilent Technologies and Eurofins Genomics Collaborate
News Mar 22, 2016
Agilent Technologies Inc. and Eurofins Genomics have announced that Agilent plans to offer custom components and an assembled plasmid service for Agilent's SureVector next-generation cloning kits through a collaboration with Eurofins. Agilent will also offer a set of catalog components for its leading-edge SureVector cloning kits, enabling the creation of over 1 million different cloning vectors.
Agilent has been a leading provider of molecular biology tools since it acquired Stratagene in 2007. It is one of the few companies whose products address the entire workflow for molecular and synthetic biology, and SureVector continues to expand this portfolio. Eurofins Genomics, a division of the Eurofins Scientific Group, is a leading provider of DNA sequencing services, genotyping services, DNA synthesis products and bioinformatics services.
The world's first modular vector kit, SureVector enables biologists to construct customized vectors-small DNA molecules within cells that can replicate independently-from standard components. "SureVector is part of Agilent's continued commitment to providing revolutionary tools for molecular biology," said Alessandro Borsatti, head of genomics marketing for Agilent. Components of the SureVector system are functional DNA modules that can be rapidly combined to assemble into vectors.
As a result, what used to take biologists two hours of hands-on time can be done in less than 30 minutes. The newly released kits contain standard parts for mammalian, E. coli and yeast cells, with Eurofins offering the ability to create custom components for any organism. "SureVector is an ideal addition to Eurofins Genomics' gene synthesis and Gene Strands services," said Uwe Koehler, head of Gene Synthesis and Molecular Biology for Eurofins Genomics.
"In this exclusive collaboration, Eurofins Genomics can now offer tailor-made SureVector plasmids, and any component of the SureVector kit can be replaced with customer-specific elements." "The Eurofins collaboration is an exciting step forward for SureVector," said Agilent's Borsatti. "It allows us to offer customers individual vectors or the ability to customize any fragment in the SureVector system."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.